Moderna Announces Booster Data, Strategy to Address Omicron Variant
Moderna, one of the manufacturers of the COVID-19 mRNA vaccines, announced preliminary neutralizing antibody data against the Omicron variant following the company's booster candidates at 50-mcg and 100-mcg dose levels. The company is continuously advancing booster candidates to address emerging variants of concern. Read more to find out how.

FDA Issues EUA for Pfizer and BioNTech COVID-19 Booster in Individuals Aged 12 Years and Older
Pfizer Inc. and BioNTech SE announced that the FDA has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 vaccine to include individuals aged 12 years and older. The booster dose is the same dosage strength (30 mcg) as the dose approved in the primary series. Read more.

Moderna Announces Positive Phase I Data for mRNA Flu Vaccine
Moderna announced the first positive interim data from the phase I study of the company's quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults. Read more.